V
VistaGen Therapeutics Inc
NASDAQ:VTGN
VistaGen Therapeutics Inc
NASDAQ:VTGN
Price:
0.61
USD
-5.03%
Market Cap:
$24.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
V
|
VistaGen Therapeutics Inc
NASDAQ:VTGN
|
US |
|
E
|
Edil San Felice SpA Societa Benefit
MIL:ESF
|
IT |
|
J
|
Jinsanjiang Zhaoqing Silicon Material Co Ltd
SZSE:301059
|
CN |
|
Vicinity Centres
ASX:VCX
|
AU |
|
B
|
Byggma ASA
OSE:BMA
|
NO |
|
E
|
Elron Ventures Ltd
TASE:ELRN
|
IL |
|
B
|
BL PharmTech Corp
KOSDAQ:065170
|
KR |
|
W
|
Woolworths Holdings Ltd
JSE:WHL
|
ZA |
|
H
|
Hyundai Hyms Co Ltd
KOSDAQ:460930
|
KR |
|
M
|
Meridian Bioscience Inc
LSE:0K0K
|
US |
|
R
|
Robinsons Land Corp
XPHS:RLC
|
PH |
|
Anhui Jianghuai Automobile Group Corp Ltd
SSE:600418
|
CN |
Relative Value
The Relative Value of one VTGN stock under the Base Case scenario is hidden USD. Compared to the current market price of 0.61 USD, VistaGen Therapeutics Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VTGN Relative Value
HIDDEN
Multiples Across Competitors
VTGN Competitors Multiples
VistaGen Therapeutics Inc Competitors
VistaGen Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
V
|
VistaGen Therapeutics Inc
NASDAQ:VTGN
|
24.2m USD | 30 | -0.5 | 0.7 | 0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20.1 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.1 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.4 | 17.3 | 12.8 | 14.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 34.3 | 11.3 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 10.9 | 129.5 | 72.4 | 80.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
